Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>This is a special one-time report on Cue Health, a company once lauded for its promise in the diagnostics sector.</li><li>Amidst diminishing fortunes, the company is under the scrutiny of significant shareholder, Tarsadia Investments.</li><li>This report aims to dissect the various valuation scenarios underpinning Cue Health, providing a lucid understanding of its investment potential amidst the unfolding drama.</li></ul>

This is a special one-time report on Cue Health, a company once lauded for its promise in the diagnostics sector.Amidst diminishing fortunes, the company is under the scrutiny of significant shareholder, Tarsadia Investments.This report aims to dissect the various valuation scenarios underpinning Cue Health, providing a lucid understanding of its investment potential amidst the unfolding drama.

Cue Health Up For Sale: Tarsadia Pushes for Desperate Sale Amid Stock Plummet!

United States

Cue Health Inc. operates as a healthcare technology company. The Company develops and manufactures medical diagnostic products which are used in clinical and at-home settings. Cue Health serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cue Health (HLTH US)

Cue Health Up For Sale: Tarsadia Pushes for Desperate Sale Amid Stock Plummet!

This is a special one-time report on Cue Health, a company once lauded for its promise in the diagnostics sector. Amidst diminishing fortunes, the...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)